Chainarong Limvarapuss, MD

Chainarong Limvarapuss, MD
21 Tiana Terrace
Lafayette, CA 94549
Tel. (707) 551 – 3300 Mobile (415) 654 - 0146
QUALIFICATIONS
Founder Solano Hematology – Oncology (private practice) July 2003
27 years of experience in clinical practice; 22 of which is self-employed
16 years of experience as Medical Director for clinical trials
4 years of experience as Chief of Medicine
8 years of experience as Vice Chief of Staff
WORK HISTORY
July 2003 to Present: Private Practice Hematologist / Oncologist Solano Hematology - Oncology INC
Sutter Solano Cancer Center, Vallejo CA
January 2016 to December 2023:
Vice chief of staff
Sutter Solano Medical Center, Vallejo CA
January 2012 to December 2015:
Chief of Medicine
Sutter Solano Medical Center, Vallejo , CA
July 2003 to June 2019: Medical Director for
Clinical Trials Sutter Solano Cancer Center, Vallejo CA
Started a new practice and cancer program in July 2003
June 2000 to July 2003: Hematologist/Oncologist at
Kingsport Hematology/Oncology
Kingsport, TN
A member of the group of five practicing at Holston Valley Medical Center, one
of the top 100 US hospitals.
December 1998-May 2000: Hematologist/Oncologist at the Carbondale Clinic
Clinical Instructor at Southern Illinois University
Carbondale, IL
Sole hematologist/oncologist of a 40-membered multispecialty group
Started up a new Hematology / Oncology services.
Teaching Faculty / Assistant professor at SIU School of Medicine.
March 1998-November 1998: Hematologist/Oncologist
Cancer Carepoint
Atlanta, GA
Locum Tenens position
EDUCATION
July 1995-February 1998: Fellowship in Hematology/Oncology
Karmanos Cancer Institute
Wayne State University, Detroit MI
An NCI designated comprehensive cancer center
July 1996-June 1995: Residency in Internal Medicine
Henry Ford Hospital, Detroit MI
An affiliated hospital of Case Western Reserve University
June 1992-June 1993: Internship in Internal Medicine
St. Luke’s Hospital, New York, NY
A major teaching hospital of Columbia University
April 1989-June 1992: Research Trainee
Hamamatsu University, Hamamatsu, Japan
Sponsored by the Japanese Government
June 1983-March 1989: Combined Undergrad. and Medical School Program
Mahidol University, Bangkok, Thailand
Doctor of Medicine (Honor)
BOARD CERTIFICATIONS
American Board of Internal Medicine-General Internal Medicine since 1995
American Board of Internal Medicine-Medical Oncology since 1998
LICENSES
States of California
PROFESSIONAL INTERESTS
Clinical Trials
Hematologic Malignancies
Breast Cancers
General Oncology/Solid Tumors
General (Benign) Hematology
PROFESSIONAL AFFILIATIONS
American College of Physician- American Society of Internal Medicine
American Medical Association
American Society of Clinical Oncology
American Society of Hematology
GRANT & RESEARCH
Treatment of CLL with Bryostatin 1 and Fludarabine: C.Limvarapuss,
RM. Mohammad and AM.Al-Katib: Funded by Berlex Laboratories:
April 1997-February 1998
SPECIAL SKILLS
Fluent in Japanese and Thai
Compassionate care and counseling
PUBLICATIONS & PRESENTATIONS
A new tubulin polymerization inhibitor, AuristatinPE, downregulates an altered
p53 and induces tumor regression in a human Waidenstrom’s Macroglobulinemia
model: C.Limvarapuss, RM.Mohammad, AM.Al-Katib et.al: Abstract and Poster
Presentation at the 39th Annual meeting of American Society of Hematology
December 5-9, 1997 San Diego, CA
Analysis of Breast Cancer data 1998: C.Limvarapuss: Memorial Hospital of
Carbondale Cancer Journal October 1999
Breast Cancer, An overview: C.Limvaraopuss: 1999 Annual Cancer
Symposium of Jackson County Medical Society October 12, 1999
Elastase Activity of Endocervical mucus in Normal Pregnancy: C. Limvarpuss,
N. Kanayama and T.Terao: Asia- Ocenia Journal of Obstretrics and Gynecology
Vol.18 No.2 June 1992
Treatment of a de novo Fludarabine resistant- CLL xenograft model with
Bryostatin 1 followed by Fludarabine: RM.Mohammad, C.Limvarapuss,
N. Hamdy, et.al.: International Journal of Oncology 1999 May:14(5):
945-50
A new tubulin polymerization inhibitor. Auristatin PE, induces tumor
regression in a human Waldenstrom’s Macroglobulinemia xenograft
model: RM.Mohammad, C.Limvarapuss, NR.Wall, etal.: International
Journal of Oncology 1999 Aug.15(2):367-72
The effect of granulocyte elastase inhibitor (urinastatin) vaginal suppository
on patients with imminent premature delivery: N.Kanayma, C.Limvarapuss,
H.Naruse, et.al.: Nippon Sanka Fujinka: Gakkai Zasshi 1992 Apr:44(4):477-82
Financial relationships
-
Attribution:SelfType of financial relationship:StockIneligible company:Olema Pharmaceuticals IncDate added:12/11/2025Date updated:03/05/2026
-
Attribution:SelfType of financial relationship:StockIneligible company:Biomea Fusion IncDate added:12/11/2025Date updated:03/05/2026Relationship end date:11/13/2025

Facebook
X
LinkedIn
Forward